AR045957A1 - Composicion farmaceutica y combinacion - Google Patents

Composicion farmaceutica y combinacion

Info

Publication number
AR045957A1
AR045957A1 ARP040103556A ARP040103556A AR045957A1 AR 045957 A1 AR045957 A1 AR 045957A1 AR P040103556 A ARP040103556 A AR P040103556A AR P040103556 A ARP040103556 A AR P040103556A AR 045957 A1 AR045957 A1 AR 045957A1
Authority
AR
Argentina
Prior art keywords
composition
prodrug
salt
mycophenolic acid
combination
Prior art date
Application number
ARP040103556A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR045957A1 publication Critical patent/AR045957A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP040103556A 2003-10-03 2004-09-30 Composicion farmaceutica y combinacion AR045957A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds

Publications (1)

Publication Number Publication Date
AR045957A1 true AR045957A1 (es) 2005-11-16

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103556A AR045957A1 (es) 2003-10-03 2004-09-30 Composicion farmaceutica y combinacion

Country Status (11)

Country Link
US (1) US20070036857A1 (OSRAM)
EP (1) EP1670437A1 (OSRAM)
JP (1) JP2007507458A (OSRAM)
AR (1) AR045957A1 (OSRAM)
AU (1) AU2004280078B2 (OSRAM)
BR (1) BRPI0414864A (OSRAM)
CA (1) CA2538099A1 (OSRAM)
MX (1) MXPA06003646A (OSRAM)
PE (1) PE20050755A1 (OSRAM)
TW (1) TW200520759A (OSRAM)
WO (1) WO2005034916A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2640283A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (mpa)
EP2094241A4 (en) * 2006-11-14 2013-04-17 Ariad Pharma Inc ORAL FORMULATIONS
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AU2009220779A1 (en) * 2008-03-05 2009-09-11 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
AU2010264116B2 (en) * 2009-06-25 2013-12-19 Dupont Nutrition Biosciences Aps Protein
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
PH12014500746A1 (en) 2011-10-06 2019-07-17 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
WO2014059309A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP7385474B2 (ja) * 2017-03-13 2023-11-22 オカヴァ ファーマシューティカルズ， インコーポレイテッド 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
ES2248793T3 (es) * 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
BR0306858A (pt) * 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
JP2006511475A (ja) * 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MXPA06003646A (es) 2006-06-05
AU2004280078A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
US20070036857A1 (en) 2007-02-15
WO2005034916A1 (en) 2005-04-21
BRPI0414864A (pt) 2006-11-28
CA2538099A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01
EP1670437A1 (en) 2006-06-21
PE20050755A1 (es) 2005-11-28
AU2004280078B2 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
AR045957A1 (es) Composicion farmaceutica y combinacion
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
AR080721A1 (es) 1-((3-ciano-piridin-2-il) metil]-3-metil-7-(2-butin-1-il)-8- (3-(r)- amino-piperidin-1-il)- xantina para tratamiento de un trastorno metabolico de un animal no humano predominantemente carnivoro
NZ606825A (en) Methods and compositions for treating complement-associated disorders
CO2019008053A2 (es) Agente terapéutico para enfermedades del hígado
WO2012112982A3 (en) Hydrogel encapsulated cells and anti-inflammatory drugs
PE20180130A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
MX2007016462A (es) Composiciones topicas para tratar la piel.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
WO2010082787A2 (ko) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
RU2020121715A (ru) Синтез эластического волокна in vivo
MX2010001711A (es) Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
PE20060507A1 (es) Composicion farmaceutica que contiene acido micofenolico con recubrimiento de liberacion modificada
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
EP1829882A3 (en) Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
WO2014140930A3 (en) Compostions and methods for enhancing the therapeutic potential of stem cells
PE20050189A1 (es) Composiciones que comprenden derivados de acido quinoloncarboxilico para administracion local

Legal Events

Date Code Title Description
FB Suspension of granting procedure